A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects With Atopic Dermatitis
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Roflumilast (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms INTEGUMENT-OLE
- Sponsors Arcutis Biotherapeutics
- 28 Aug 2024 Results published in an Arcutis Biotherapeutics media release.
- 28 Aug 2024 According to an Arcutis Biotherapeutics media release, today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05% demonstrating the durable efficacy and favorable safety profile of roflumilast cream 0.05% in the treatment of mild to moderate AD in children 2 to 5 years old.
- 10 Jun 2024 According to an Arcutis Biotherapeutics media release, Melinda Gooderham is investigator in this trial.